Reviva pharmaceuticals holdings, inc. reports third quarter 2021 financial results and recent business highlights

- initiation of a pivotal phase 3 trial evaluating the efficacy and safety of brilaroxazine for the treatment of schizophrenia expected by year-end -
RVPH Ratings Summary
RVPH Quant Ranking